Evofosfamide (TH-302)

For research use only.

Catalog No.S2757 Synonyms: Evofosfamide

2 publications

Evofosfamide (TH-302) Chemical Structure

CAS No. 918633-87-1

Evofosfamide (TH-302) is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.

Selleck's Evofosfamide (TH-302) has been cited by 2 publications

Purity & Quality Control

Biological Activity

Description Evofosfamide (TH-302) is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.
In vitro

TH-302 is selectively potent under hypoxia and stable to liver microsomes. Substitution of the chlorine with bromine on the phosphorus mustard in 3b increases the potency by 10-fold and maintaines the high hypoxic selectivity [Hypoxia cytotoxicity ratio (HCR) = 270]. In both human lung cancer H460 cells and human colon cancer HT29 cells, potent cytotoxicity of TH-302 is observed under N2. TH-302 inhibits H460 cells and HT29 cells with IC90 of 0.1 μM and 0.2 μM, respectively. [1] TH-302 shows much enhanced potency in H460 spheroids compared to H460 monolayer cells under normoxia. [2] TH-302 exhibits potent cytotoxicity to MM cells with hypoxic selectivity and dose dependency. TH-302 can induce G0/G1 cell-cycle arrest under hypoxic conditions. The effect of TH-302 on cell-cycle machinery is mediated by down-regulating cyclin D1/2/3, CDK4/6, p21cip-1, p27kip-1, and pRb expression, whereas CDK2 expression remained undisturbed. TH-302 can induce dose-dependent apoptosis in both human and murine MM cells in hypoxic conditions. TH-302-activated apoptosis is mediated through down-regulating the antiapoptotic proteins BCL-2 and BCL-xL, as well as up-regulating the expression of cleaved proapoptotic protein caspase-3, -8, and -9 and poly ADP-ribose polymerase. In contrast to the hypoxia-specific toxicity, TH-302 shows very low toxicity in normoxic condition, even at high concentrations. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H460 NYW3WIZmS3m2b4TvfIlkcXS7IHHzd4F6 MWWyJIhzew>? NF71eHhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJIFnfGW{IEKgbJJ{KGK7IFHsZY1ieiCkbIXlJJN1[WmwaX7nJIF{e2G7LDDJR|UxRTBwMEG5{txONg>? M2TWc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkW3OVQ1Lz5zOEK1O|U1PDxxYU6=
H460 Mk\5R5l1d3SxeHnjbZR6KGG|c3H5 M2rWWFIhcHK| M1jXZ2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMhfW6mZYKgbJlxd3irYzDjc45lcXSrb36gZYZ1\XJiMjDodpMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO5NF0xNjIQvF2u NVjDSGJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyOVc2PDRpPkG4NlU4PTR2PD;hQi=>
HT29 NWjPRXd7S3m2b4TvfIlkcXS7IHHzd4F6 NE[z[ZQzKGi{cx?= M{XCbmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVOjliY3XscJMhfW6mZYKgbJlxd3irYzDjc45lcXSrb36gZYZ1\XJiMjDodpMh[nliY3zvco9o\W6rYzDhd5NigSxiSVO5NF0xNjMQvF2u MnPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NUe1OFQoRjF6MkW3OVQ1RC:jPh?=
H460 MnLUR5l1d3SxeHnjbZR6KGG|c3H5 NUTWXo5[OiCqcoO= NIjx[ZREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJPDZyIHPlcIx{KHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBi\nSncjCyJIhzeyCkeTDBcIFu[XJiYnz1[UB{fGGrbnnu[{Bie3OjeTygTWM2OD13LkJOwG0v Mkn4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NUe1OFQoRjF6MkW3OVQ1RC:jPh?=
H460 Mn63R5l1d3SxeHnjbZR6KGG|c3H5 M{HvdlIhcHK| NYHtPXFvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h[W[2ZYKgNkBpenNiYomgZ4xwdm:pZX7pZ{Bie3OjeTygTWM6OD1|MN88UU4> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ3N{W0OEc,OTh{NUe1OFQ9N2F-
HT29 MXLDfZRwfG:6aXPpeJkh[XO|YYm= NFvUU|gzKGi{cx?= M1TocmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVOjliY3XscJMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;uJIFnfGW{IEKgbJJ{KGK7IHPsc45w\2WwaXOgZZN{[XluIFnDPVA:PDEQvF2u MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ3N{W0OEc,OTh{NUe1OFQ9N2F-
NCI-H460 M1rYOGN6fG:2b4jpZ4l1gSCjc4PhfS=> MXOyOEBpenN? M4HHUWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy|IIDy[ZRz\WG2ZXSg[o9zKDJ2IHjyd{B2dmSncjDofZBwgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT6wPO69VS5? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh|NUC5PVc9N2F-
HT-29 NH3aW2FEgXSxdH;4bYNqfHliYYPzZZk> M3;6fVI1KGi{cx?= M{S2PWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCob3zsc5dm\CCkeTDjc41xd3WwZDD3ZZNpd3W2IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PDlwNUJOwG0v NEDOVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NFk6Pyd-MkizOVA6QTd:L3G+
NCI-H460 MYPDfZRwfG:6aXPpeJkh[XO|YYm= MmXPNlQhcHK| NXvkT4Y2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgZYZ1\XJiMkSgbJJ{KHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJIJ6KGy3bXnu[ZNk\W6lZT3iZZNm\CCFZXzsMXRqfGW{IFfsc{Bie3OjeTygTWM2OD1yLkCwPVPPxE1w Mmq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyN{m0O|QoRjJ7MEe5OFc1RC:jPh?=
NCI-H460 NWTwbWE3S3m2b4TvfIlkcXS7IHHzd4F6 M3XXe|I1KGi{cx?= NF72dGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSES2NEBk\WyuczDh[pRmeiB{NDDodpMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;uJIJ6KGy3bXnu[ZNk\W6lZT3iZZNm\CCFZXzsMXRqfGW{IFfsc{Bie3OjeTygTWM2OD14Lk[1{txONg>? MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyN{m0O|QoRjJ7MEe5OFc1RC:jPh?=
DU145 MkfJR5l1d3SxeHnjbZR6KGG|c3H5 M{fLb|IhcHK| MXTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{BqdmO3YnH0[YQh\m:{IEKgbJJ{KHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XJiYnz1[UBie3OjeTygTWM2OD12LkG0{txONg>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ3OUe0Okc,Ojl{NUm3OFY9N2F-
PC3 MlHzR5l1d3SxeHnjbZR6KGG|c3H5 NF\lXXQzKGi{cx?= NEPsSXhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMhcW6ldXLheIVlKG[xcjCyJIhzeyC3bnTldkBpgXCxeHnjJINwdmSrdHnvckBu\WG|dYLl[EBi\nSncjC3NkBpenNiYomgRYxidWG{IHLseYUh[XO|YYmsJGlEPTB;Nj60Pe69VS5? MkLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NUm3OFYoRjJ7MkW5O|Q3RC:jPh?=
HEMC-SS NYq0eJdPSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1zJWVI1KGi{cx?= NIKzS|ZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjFUWMuW1NiY3XscJMhfHKnYYTl[EBnd3JiMkSgbJJ{KHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3itc5V1KGGwZDDpcoN2[mG2ZXSgeY5l\XJibn;ycY95cWNiY3;u[Il1cW:wIH\vdkA1QCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NE4yO87:TT6= NVXFXnlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxPVk4ODVpPkOwNVk6PzB3PD;hQi=>
HEMC-SS NH;vbVBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlzQNlQhcHK| NYm4OXZFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDISW1ENVOVIHPlcIx{KHS{ZXH0[YQh\m:{IEK0JIhzeyC3bnTldkBvd3Kvb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbE1wfXRiYX7kJIlv[3WkYYTl[EB2dmSncjDuc5Jud3irYzDjc45lcXSrb36g[o9zKDR6IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0zNjoQvF2u NYq0R4trRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxPVk4ODVpPkOwNVk6PzB3PD;hQi=>
NCI-H460 M{TmOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MlrORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{BqdiCycnXz[Y5k\SCxZjDONkwhUUN3ME2y{txONg>? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7NUS3O{c,OzB{OUW0O|c9N2F-
NCI-H460 NELaZ|lCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M3nHcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMhcW5icILld4Vv[2Vib3[gU|ItKEmFNUC9NlXPxE1w NIfZSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5OVQ4Pyd-M{CyPVU1Pzd:L3G+
MDA-MB-468 Mk[4R5l1d3SxeHnjbZR6KGG|c3H5 M2PCNVQhcHK| MlTKR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDpcoN2[mG2ZXSg[o9zKDRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgZY5lKG2nYYP1doVlKGGodHXyJFUh\GG7czDifUBUWkJiYYPzZZktKEmFNUC9NE4xODZ{zszNMi=> NHvpTJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEi4OVY5OCd-M{C4PFU3QDB:L3G+
SW620 MWHDfZRwfG:6aXPpeJkh[XO|YYm= MYW0JIhzew>? MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{BqdmO3YnH0[YQh\m:{IESgbJJ{KHWwZHXyJIh6eG:6aXOgZ49v\Gm2aX;uJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQh[W6mIH3lZZN2emWmIHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFnDOVA:OC5yNUNOwG0v NHnsZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEi4OVY5OCd-M{C4PFU3QDB:L3G+
MDA-MB-468 MUnDfZRwfG:6aXPpeJkh[XO|YYm= NEPJZ2w1KGi{cx?= NV\3cFNQS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{BqdmO3YnH0[YQh\m:{IESgbJJ{KHWwZHXyJIFmem:kaXOgZ49v\Gm2aX;uJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQh[W6mIH3lZZN2emWmIHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFnDOVA:PC52MEROwG0v MlPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB6OEW2PFAoRjNyOEi1OlgxRC:jPh?=
SW620 NXrZXFR3S3m2b4TvfIlkcXS7IHHzd4F6 MlPXOEBpenN? MlvaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV3c3OjBiY3XscJMhcW6ldXLheIVlKG[xcjC0JIhzeyC3bnTldkBi\XKxYnnjJINwdmSrdHnvckBnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KGGwZDDt[YF{fXKnZDDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDJR|UxRTJyLkdOwG0v NVzSfFdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{C4PFU3QDBpPkOwPFg2PjhyPD;hQi=>

... Click to View More Cell Line Experimental Data

In vivo TH302 inhibits primary tumor growth by 41% on day 25 after implantation, whereas TH302 plus gemcitabine (a nucleoside analog) inhibits primary tumor growth by 96% on day 25. [1] When TH-302 is administered at 6.25, 12.5, 25, or 50 mg/kg in the H460 NSCLC xenograft model QD × 5/wk × 2 wks (once a day for 5 days per week for 2 weeks) i.p., the tumor growth inhibition at Day 22 is 43%, 51%, 75%, and 89%, respectively. TH-302 at 100 mg/kg shows a decrease in blood cell counts 3 days after treatment end, but is totally recovered 7 days post-treatment. TH-302 under all tested regimens exhibits efficacy metrics ranging from 58% to 89% tumor growth inhibition. TH-302 induced cell killing is breathing oxygen concentration dependent, with the greatest cytotoxicity occurring when the tumor-bearing mice are exposed to low oxygen concentrations. Tumor growth is significantly reduced by TH-302 in animals breathing 10% O2 compared with 95% O2 breathing. After TH-302 treatment, the pimonidazole-positive area is significantly decreased at 48 hours after dosing (6.3 % in vehicle vs. 1.8 % in the TH-302 treatment group). [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Human H460 or HT29 cells
  • Concentrations: 0.01 -1 μM
  • Incubation Time: 2 hours
  • Method: Exponentially growing human H460 or HT29 cells are seeded into 60 mm notched glass plates at 3 × 105 cells per plate and grown in RPMI medium supplemented with 10% fetal bovine serum for 2 days prior to initiating treatment. On the day of the test, TH-302 stocks of known concentrations are prepared in complete medium and 2 mL of the desired stock is added to each plate. The plates are placed in either an anaerobic chamber or a standard tissue-culture incubator. The anaerobic chamber is evacuated and gassed with the anaerobic gas mixture (90% N2/5% CO2/5% H2) to create a hypoxic environment. Cells are then incubated with TH-302 for 2 hours at 37 °C. At the end of treatment, plates are removed from each vessel and washed with phosphate-buffered saline and a solution of trypsin-EDTA and then trypsinized for 5 min at 37 °C. Detached cells are neutralized with medium plus serum and spun for 5 min at 100g. Cells are resuspended at approximately 1 × 106 cells/mL and diluted 10-fold for plating. The exact concentration of each stock is determined. Known numbers of cells are plated and placed undisturbed in an incubator for between 9 and 13 days. Colonies are fixed and stained with a solution of 95% ethanol with 0.25% crystal violet stain. Colonies of greater than 50 cells are counted, and the surviving fraction is determined. Plating efficiencies (PEs) are determined by dividing the number of colonies by the actual number of cells plated. Surviving fractions are calculated by dividing the PEs of treated cells by the PEs of untreate
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: H460, Calu-6, PC-3, H82, A375, Stew2, 786-O, PLC/PRF/5, Hs766t, BxPC-3, and SU.86.86 xenografts are established in NCI SCID female mice.
  • Dosages: 50 mg/kg
  • Administration: Intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (200.42 mM)
Water 10 mg/mL warmed (22.26 mM)
Ethanol '90 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 449.04
Formula

C9H16Br2N5O4P

CAS No. 918633-87-1
Storage powder
in solvent
Synonyms Evofosfamide
Smiles CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02020226 Unknown status Drug: TH-302 Solid Tumors Threshold Pharmaceuticals November 2013 Phase 1
NCT01833546 Completed Drug: Evofosfamide|Drug: Gemcitabine Solid Tumor|Pancreatic Cancer Merck KGaA Darmstadt Germany|Threshold Pharmaceuticals April 18 2013 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Others Products

Tags: buy Evofosfamide (TH-302) | Evofosfamide (TH-302) supplier | purchase Evofosfamide (TH-302) | Evofosfamide (TH-302) cost | Evofosfamide (TH-302) manufacturer | order Evofosfamide (TH-302) | Evofosfamide (TH-302) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID